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Abstract 
Stem cell therapy is a rapidly evolving area of research in regenerative medicine. 
Mesenchymal stem cells (MSCs) have received considerable attention by the scientific 
community because of their potential of expansion and the ability to differentiate into 
various mesodermal tissues. Liposomes are well-established non-viral carrier systems, 
presenting significant advantages over other nanoparticle-based drug delivery systems, 
namely a high load carrying capacity, a relative safety and an ease of large-scale 
production, as well as a versatile nature in terms of possible formulation and 
functionalization. The objectives of the present study were to evaluate the efficacy of 
growth differentiation factor-releasing liposomes on the induction of MSCs 
osteogenesis.  For that, dexamethasone (Dex) was encapsulated within the liposome 
bilayer at different lipid formulations. The obtained liposomes showed a monodisperse 
distribution of particles size, and an increased ζ- potential for the PEGylated liposomes. 
Dex encapsulation studies demonstrate that the presence of cholesterol (Chol) decreases 
the Dex loading capacity of the liposome bilayer. The different stabilizing effect of Chol 
and Dex on the liposomes is due to differences in their interaction with phospholipid 
molecules. Highly lipophilic Chol gets incorporated between the acyl chains and 
reduces chain movement increasing rigidity and stabilization the membrane. Dex, being 
more hydrophilic, interacts differently with phospholipid acyl chains and head groups 
and destabilizes the membrane. In vitro release study demonstrated an initial burst 
release within an initial timeframe of 24 hours. Following the initial release, a slower 
release was observed until 6 days. Afterwards, Dex continues to be released at a slower 
but steady rate until day 21. The effect of Dex-loaded liposomes on viability, 
proliferation and osteogenic differentiation of human bone marrow-derived 
mesenchymal stem cells (hBMSCs) was assessed. The results of the biological activity 
showed that the Dex-loaded liposomes do not have any cytotoxic effect and, more 
importantly, were able to promote an earlier induction of hBMSCs differentiation into 
the osteogenic lineage, as demonstrated by the expression of osteoblastic markers at the 
phenotypic and the genotypic levels. Concluding, Dex-loaded liposomes represent a 
novel biological or nature-inspired nanoparticle strategy for tissue engineering and 
regenerative medicine applications. 
 
 
